High Dose Intravenous Ascorbic Acid in Severe Sepsis
Primary Purpose
Sepsis
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ascorbic Acid
Normal Saline
Sponsored by
About this trial
This is an interventional treatment trial for Sepsis
Eligibility Criteria
Inclusion Criteria:
Patients with:
- A suspected or confirmed infection with an order for intravenous antibiotics or antivirals
- The presence of acute sepsis-induced organ dysfunction
Definition of organ dysfunction:
- Arterial hypoxemia [PaO2 /FiO2 < 300]
- Hypotension [systolic blood pressure (SBP) < 90 mmHg or SBP decrease > 40 mmHg]
- Lactic acidosis [lactate > 2.5 mmol/L]
- Acute kidney injury [creatinine >2.0 or urine output < 0.5 ml/kg/hr for >2 hours despite fluid resuscitation]
- Thrombocytopenia [platelet count < 100,000]
- Acute coagulopathy [international normalized ratio (INR) > 1.5]
- Hepatic failure [bilirubin > 2 mg/dL].
- Predisposition, Infection, Response, and Organ Failure (PIRO) score ≥ 10
Exclusion Criteria:
- Age < 18 years
- Pregnancy or breastfeeding
- Requirement for immediate surgery within the treatment protocol timeframe
- Inability to obtain written informed consent from subject or surrogate
- Patient to receive comfort measures only
Sites / Locations
- Chrisitana Care Health System-Christiana Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
High dose IV ascorbic acid
Placebo
Arm Description
Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
Outcomes
Primary Outcome Measures
Change in Modified SOFA Score
Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater degree of dysfunction.
Secondary Outcome Measures
Modified SOFA Score
Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater dysfunction.
Ascorbic Acid Concentration at 32 Hours
Ascorbic Acid Concentration Normal Ascorbic Acid Range 0.4-2.0 mg/dL
ICU Length of Stay
ICU Length of Stay in Hours
Hospital Length of Stay
From admission until discharge from ICU in days
Change in PIRO Score
PIRO consists of 4 assessments, Predisposition (scored 0-9), Infection (scored 0-4), Response (scored 0-6), and Organ Failure (scored 0-14) (PIRO). The total PIRO score is the sum of all subscores and ranges from 0-33 with higher scores indicating worse health.
Percentage of Participants Who Died
Full Information
NCT ID
NCT02734147
First Posted
March 18, 2016
Last Updated
January 28, 2021
Sponsor
Christiana Care Health Services
1. Study Identification
Unique Protocol Identification Number
NCT02734147
Brief Title
High Dose Intravenous Ascorbic Acid in Severe Sepsis
Official Title
The Efficacy of Intravenous Ascorbic Acid in Patients With Severe Sepsis
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Terminated
Why Stopped
The trial prematurely terminated due to the loss of funding.
Study Start Date
April 1, 2016 (undefined)
Primary Completion Date
October 8, 2017 (Actual)
Study Completion Date
November 23, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Christiana Care Health Services
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Despite an organized treatment approach outlined in expert-consensus guidelines for sepsis with fluid resuscitation to treat hypovolemia, antibiotics to target the infectious insult, and vasopressors for hypotension, mortality rates for sepsis remain high and the incidence continues to rise, making sepsis the most expensive inpatient disease.
Recent research has described the therapeutic benefits associated with ascorbic acid treatment for sepsis.
Researchers objectives are to perform a randomized-controlled clinical trial investigating the ability of ascorbic acid(vitamin C) administration to decrease organ dysfunction in severe sepsis. The widespread occurrence of microvascular dysfunction in sepsis leading to tissue hypoxia, mitochondrial dysfunction, and adenosine triphosphate (ATP) depletion, gives rise to organ failure.
Patients with organ failure and sepsis (severe sepsis) are at a higher risk of death than patients with organ failure alone. Critically ill patients may have an increased requirement for ascorbic acid in sepsis and these patients frequently have levels below normal. Ascorbic acid administration, has been shown to correlate inversely with organ failure (human literature) and directly with survival (animal studies).
4,5 Intravenous ascorbic acid therapy decreases organ failure by providing a protective effect on several microvascular functions including improving capillary blood flow, decreasing microvascular permeability, and improving arteriolar responsiveness to vasoconstrictors. Defining the utility of novel agents to augment researchers care for severe sepsis is an important task as investigators continue the institutional focus on sepsis care.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
High dose IV ascorbic acid
Arm Type
Active Comparator
Arm Description
Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
Intervention Type
Drug
Intervention Name(s)
Ascorbic Acid
Intervention Type
Other
Intervention Name(s)
Normal Saline
Primary Outcome Measure Information:
Title
Change in Modified SOFA Score
Description
Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater degree of dysfunction.
Time Frame
Baseline and 72 hours
Secondary Outcome Measure Information:
Title
Modified SOFA Score
Description
Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater dysfunction.
Time Frame
at 72 Hours
Title
Ascorbic Acid Concentration at 32 Hours
Description
Ascorbic Acid Concentration Normal Ascorbic Acid Range 0.4-2.0 mg/dL
Time Frame
32 Hours
Title
ICU Length of Stay
Description
ICU Length of Stay in Hours
Time Frame
Length of ICU stay up to 200 hours
Title
Hospital Length of Stay
Description
From admission until discharge from ICU in days
Time Frame
From ICU admission through ICU discharge, up to 2 weeks
Title
Change in PIRO Score
Description
PIRO consists of 4 assessments, Predisposition (scored 0-9), Infection (scored 0-4), Response (scored 0-6), and Organ Failure (scored 0-14) (PIRO). The total PIRO score is the sum of all subscores and ranges from 0-33 with higher scores indicating worse health.
Time Frame
Baseline and 72 hours
Title
Percentage of Participants Who Died
Time Frame
From initial hospital admission through discharge, up to 2 weeks.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with:
A suspected or confirmed infection with an order for intravenous antibiotics or antivirals
The presence of acute sepsis-induced organ dysfunction
Definition of organ dysfunction:
Arterial hypoxemia [PaO2 /FiO2 < 300]
Hypotension [systolic blood pressure (SBP) < 90 mmHg or SBP decrease > 40 mmHg]
Lactic acidosis [lactate > 2.5 mmol/L]
Acute kidney injury [creatinine >2.0 or urine output < 0.5 ml/kg/hr for >2 hours despite fluid resuscitation]
Thrombocytopenia [platelet count < 100,000]
Acute coagulopathy [international normalized ratio (INR) > 1.5]
Hepatic failure [bilirubin > 2 mg/dL].
Predisposition, Infection, Response, and Organ Failure (PIRO) score ≥ 10
Exclusion Criteria:
Age < 18 years
Pregnancy or breastfeeding
Requirement for immediate surgery within the treatment protocol timeframe
Inability to obtain written informed consent from subject or surrogate
Patient to receive comfort measures only
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ryan Arnold, MD
Organizational Affiliation
Christiana Care Health Services
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jamie Rosini, PharmD
Organizational Affiliation
Christiana Care Health Services
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chrisitana Care Health System-Christiana Hospital
City
Newark
State/Province
Delaware
ZIP/Postal Code
19718
Country
United States
12. IPD Sharing Statement
Learn more about this trial
High Dose Intravenous Ascorbic Acid in Severe Sepsis
We'll reach out to this number within 24 hrs